Auriculasin

Overview

Auriculasin is an anticancer agent that inhibits VEGFR2 , PI3K/AKT/mTOR , MAPK . Auriculasin can inhibit cell proliferation, induce cell apoptosis , and inhibit angiogenesis, and promotes mitochondrial oxidative stress and ferroptosis . Auriculasin is also active at the cannabinoid receptor CB1 with an IC 50 of 8.92 μM. Auriculasin can be used in cancer research, especially related diseases such as prostate cancer and non-small cell lung cancer , as well as research on the development of anti-angiogenic drugs.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > PI3K | Products > Signaling Pathways > Cannabinoid Receptor | Products > Signaling Pathways > Ferroptosis | Products > Signaling Pathways > mTOR | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > VEGFR | Products > Signaling Pathways > Akt

Product Information

• Catalog No.: HY-N2911
• CAS No.: 60297-37-2
• Molecular Formula: C25H24O6
• Molecular Weight: 420.45
• Purity: 98.54%
• Storage: -20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Availability: In-stock

Source

Original product source